1. Scrip

Gilead Completes HCV Clinical Development With Vosevi Approval

 
• By Joseph Haas

Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.

Gilead Sciences Inc. obtained US approval – about three weeks ahead of an Aug. 8 user fee date – for its final hepatitis C product incorporating the nucleoside polymerase inhibitor sofosbuvir as the US FDA okayed Vosevi (sofosbuvir/velpatasvir/voxilaprevir) July 18 as a treatment for HCV-infected patients who have failed prior therapy with a direct-acting antiviral regimen.

With the Foster City, Calif.-based firm earlier this year slashing sales guidance for its HCV franchise, the Vosevi approval can be seen as virtually the end of an era for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.